Clinical trials: Progesterone Receptor Positive Tumor
Estrogen Receptor-positive Breast Cancer, Gastrinoma
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer
- Trial name
- NCT02273752
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated postmenopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast…
- Conditions
- Metastatic Breastcancer, Estrogen Receptor Positive Breast Cancer, Estrogen Receptor Negative Neoplasm, Progesterone Receptor Positive Tumor
- Trial name
- ARTT (NCT02000375)
- Testing
- DHEA
- Where
- 8 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Estrogen Receptor Negative, Estrogen Receptor Positive
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative
- Trial name
- NCT01281163
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Progesterone Receptor Positive Tumor
A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer
The aim of this study is to increase, by DHA-induced chemosensitization, the activity of anticancer chemotherapy in patients with a metastatic advanced breast cancer, by a nutritional approach with marin-derived PolyUnsaturated…
- Conditions
- Metastatic Breast Cancer, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor, HER-2 Negative Tumor
- Trial name
- DHALYA (NCT01548534)
- Testing
- Dietary supplementation with fish oil., Dietary supplementation with vegetable oil
- Where
- 11 sites in France
- Volunteers
- 65 people
- Sponsor
- University Hospital, Tours
Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma.
- Trial name
- NCT02052128
- Testing
- onapristone
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Arno Therapeutics
Adult Solid Neoplasm, Estrogen Receptor Negative
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors.
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01281150
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00057941
- Testing
- anastrozole, gefitinib, fulvestrant
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Patients in Premenopausal, Estrogen and/or Progesterone Receptor Positive
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies.
- Trial name
- NCT02132000
- Testing
- toremifene or tamoxifen
- Where
- China
- Volunteers
- 3,036 people
- Sponsor
- Fengxi Su
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
This phase I trial is studying the side effects and best dose of RO4929097 when given together with letrozole in treating post-menopausal women with stage II or stage III breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01208441
- Testing
- letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT01100489
- Testing
- external beam radiation therapy, questionnaire administration, therapeutic conventional surgery
- Where
- 3 sites in United States
- Sponsor
- Case Comprehensive Cancer Center